Notable ETF Outflow Detected - IXJ, SYK, DHR, MDT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2025
0mins
Source: NASDAQ.COM
Current Share Price Analysis: IXJ's current share price is $85.32, which is between its 52-week low of $80.681 and high of $101.305, indicating a potential area for technical analysis using the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function similarly to stocks, with units that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 313.500
Low
390.00
Averages
430.32
High
465.00
Current: 313.500
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seeking Stable Dividend Growth Amid Market Turbulence
- Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
- Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
- Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
- Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
See More
Stryker Acquires Amplitude Vascular for Up to $835M
- Acquisition Scale: Stryker's acquisition of Amplitude Vascular Systems for up to $835 million marks a significant milestone in expanding its peripheral vascular portfolio, expected to enhance its market position in treating calcified peripheral arterial disease.
- Technological Innovation: Amplitude's next-generation hydraulic intravascular lithotripsy platform offers a new solution for treating calcified peripheral arterial disease, potentially improving patient outcomes and strengthening Stryker's competitive edge in the medical technology sector.
- Strategic Partnership Background: Venture capital firm BioStar Capital served as an early strategic growth partner for Amplitude, providing IP licensing, initial startup capital, and guidance through various development phases and clinical studies, showcasing a robust support network for the startup.
- Future Outlook: Despite recent cyber incidents, Stryker maintains its 2026 outlook of 8%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10, indicating confidence in future growth and adaptability in the market.
See More
BioStar Capital Achieves Landmark Exit in Cardiovascular Technology
- Technological Innovation: Amplitude Vascular Systems (AVS) has developed a next-generation hydraulic lithotripsy technology that offers a new alternative for treating calcified peripheral artery disease, potentially reducing the annual treatment costs of approximately $100 billion significantly.
- Strategic Acquisition: Stryker's acquisition of AVS for up to $835 million marks a milestone in expanding its peripheral vascular portfolio, further solidifying its leadership position in the medical technology sector.
- Local Roots: All three companies have strong ties to Michigan, with BioStar Capital's founder, Louis Cannon, first encountering hydraulic lithotripsy technology while serving on the University of Michigan's Coulter Committee, which propelled the technology's development.
- Successful Exit: This acquisition represents the latest successful exit for BioStar Capital, which has previously invested in several medical technology firms, including Corindus Vascular Robotics, acquired by Siemens for $1.1 billion.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Analysis of Stryker Corporation's Profit Outlook
- Profit Impact Analysis: Stryker Corporation's profits were reduced by $684 million due to unusual items over the past year; however, analysts believe these expenses may be one-off, suggesting potential for future profit improvement.
- Future Profit Expectations: Assuming no similar unusual expenses arise in the future, Stryker is expected to see a significant profit increase next year, reflecting an optimistic outlook for the company's earnings potential.
- Earnings Per Share Growth: Over the past three years, Stryker's earnings per share have grown at an annual rate of 26%, indicating a sustained improvement in profitability despite facing short-term challenges.
- Risk Warning: While the profit outlook appears positive, analysts have identified one warning sign that investors should monitor to gain a comprehensive understanding of Stryker's financial health.
See More
Seeking Stable Dividend Growth Amid Market Turbulence
- Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
- Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
- Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
- Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
See More
Stryker Acquires Amplitude Vascular for Up to $835M
- Acquisition Scale: Stryker's acquisition of Amplitude Vascular Systems for up to $835 million marks a significant milestone in expanding its peripheral vascular portfolio, expected to enhance its market position in treating calcified peripheral arterial disease.
- Technological Innovation: Amplitude's next-generation hydraulic intravascular lithotripsy platform offers a new solution for treating calcified peripheral arterial disease, potentially improving patient outcomes and strengthening Stryker's competitive edge in the medical technology sector.
- Strategic Partnership Background: Venture capital firm BioStar Capital served as an early strategic growth partner for Amplitude, providing IP licensing, initial startup capital, and guidance through various development phases and clinical studies, showcasing a robust support network for the startup.
- Future Outlook: Despite recent cyber incidents, Stryker maintains its 2026 outlook of 8%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10, indicating confidence in future growth and adaptability in the market.
See More
BioStar Capital Achieves Landmark Exit in Cardiovascular Technology
- Technological Innovation: Amplitude Vascular Systems (AVS) has developed a next-generation hydraulic lithotripsy technology that offers a new alternative for treating calcified peripheral artery disease, potentially reducing the annual treatment costs of approximately $100 billion significantly.
- Strategic Acquisition: Stryker's acquisition of AVS for up to $835 million marks a milestone in expanding its peripheral vascular portfolio, further solidifying its leadership position in the medical technology sector.
- Local Roots: All three companies have strong ties to Michigan, with BioStar Capital's founder, Louis Cannon, first encountering hydraulic lithotripsy technology while serving on the University of Michigan's Coulter Committee, which propelled the technology's development.
- Successful Exit: This acquisition represents the latest successful exit for BioStar Capital, which has previously invested in several medical technology firms, including Corindus Vascular Robotics, acquired by Siemens for $1.1 billion.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Analysis of Stryker Corporation's Profit Outlook
- Profit Impact Analysis: Stryker Corporation's profits were reduced by $684 million due to unusual items over the past year; however, analysts believe these expenses may be one-off, suggesting potential for future profit improvement.
- Future Profit Expectations: Assuming no similar unusual expenses arise in the future, Stryker is expected to see a significant profit increase next year, reflecting an optimistic outlook for the company's earnings potential.
- Earnings Per Share Growth: Over the past three years, Stryker's earnings per share have grown at an annual rate of 26%, indicating a sustained improvement in profitability despite facing short-term challenges.
- Risk Warning: While the profit outlook appears positive, analysts have identified one warning sign that investors should monitor to gain a comprehensive understanding of Stryker's financial health.
See More
